fda update on semaglutide The has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, for weight loss and long-term weight maintenance in certain adult patients—in just 54 days from filing Compounded Semaglutide & Tirzepatide 2025:
Description
Both treatments can cause digestive side effects because they act on hormone pathways involved in appetite and digestion
A gaunt appearance is not necessarily beautiful, and can be associated with facial aging, and certain medical conditions
It provides a daily alternative for those wanting weight loss medication without injections
Twin Res Hum Genet
SYH9017 leverages CSPC's proprietary long-acting delivery technology to enable monthly dosing, potentially offering a meaningful improvement in patient convenience and adherence compared with currently marketed weekly GLP-1 therapies
Bolignano D, Zoccali C
